Open-Angle Glaucoma
Conditions
Keywords
Hydrus Microstent, OMNI Surgical System, Phacoemulsification
Brief summary
Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis
Detailed description
The use of combination Phacoemulsification, OMNI Canaloplasty and Hydrus microstent successfully lowers IOP in ethnically-diverse patients with Open Angle Glaucoma
Interventions
PROCEDUREReal-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis
The use of combination Phacoemulsification, OMNI Canaloplasty and Hydrus microstent successfully lowers IOP in ethnically-diverse patients with Open Angle Glaucoma
Sponsors
Alcon, a Novartis Company
Barnet Dulaney Perkins Eye Centers
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects with h/o CEIOL/OMNI/Hydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data * have Glaucoma
Exclusion criteria
* Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies. * Patients with refractory CME or CME persisting 3 months or more post-operatively * Patients with incomplete IOP, medication logs or VF data within post-operative period * Prior incisional surgery or MIGS
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measured Efficacy of Surgical Process with Phacoemulsification | 24 months | Primary endpoint stratified by complete or qualified success: • Proportion of patients with complete success (%) - without the use of medications |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Additional Benefits of the Surgical System and Phacoemulsification | 36 months | • Proportion of patients with qualified success (%) - with glaucoma meds without increase from baseline |
Countries
United States
Contacts
Primary ContactDerek J Arnson, Master of Education
Backup ContactChristine Funke, Medical Doctor
Outcome results
None listed